Keywords: Novartis, Jakavi, Myelofibrosis, UK, NICE, Draft guidance

UK's NICE says no to Novartis' Jakavi for myelofibrosis in draft guidance

Article | 13 February 2013

Print This

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (February 13) issued new draft guidance not ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in